Targeting ferroptosis with the lipoxygenase inhibitor PTC 041 as a therapeutic strategy for the treatment of Parkinson's disease PLOS One PDF) Glutathione Deficiency in Parkinson's Disease: Intranasal Administration as a Method of Augmentation Evidence for Glutathione Deficiency Frontiers Neurodegenerative disease and antioxidant biomarkers: A bidirectional Mendelian randomization study Targeting the Cysteine Redox Proteome in Parkinson's Disease: The Role of Glutathione Precursors and Beyond